As Richmond Pharmacology approaches its 20th anniversary our co-founder and CEO reflects on the developments, regulatory changes, and innovations within the life science industry in an article in the PharmaTimes. To read the full article, click here


Established in 2001 in partnership with St George’s University of London, Richmond Pharmacology’s aim was to create a structure where practising physicians were actively involved in clinical research. Profits were reinvested into the business or used to fund academic research in underfunded areas - leading to the creation of Richmond Research Institute in 2020.


Two decades later and the landscape of early phase clinical research has changed dramatically. Moving from small molecules whose effects were studied for numerous medical conditions to therapeutics such as mRNA, siRNA, and gene editing which treat specific disease pathways. 


This progressive course of education and regulatory environment must continue if we are to align with the advancements in precision medicine. 


Read Dr Taubel’s full reflection in the PharmaTimes.

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event